Biochemical Study in Ehrlich Carcinoma Cells-bearing Mice Treated with Arsenic Trioxide and Cisplatin | ||
| Advances in Environmental and Life Sciences | ||
| Article 4, Volume 1, Issue 1, January 2022, Pages 40-47 PDF (907.4 K) | ||
| Document Type: Original research articles | ||
| DOI: 10.21608/aels.2022.114990.1005 | ||
| Authors | ||
| Wafaa M M Ibrahim1; Sally M Foad2; Ahmed Yousef El touhky* 2 | ||
| 1Medical Biochemistry Department, Faculty of Medicine, Tanta University, 31527, Tanta, Egypt | ||
| 2Chemistry Department, Faculty of Science, Suez Canal University, 41522 Ismailia, Egypt. | ||
| Abstract | ||
| The purpose of the study was to evaluate the effect of arsenic trioxide and cisplatin on Ehrlich ascites carcinoma (EAC) bearing mice. Fifty female Albino mice were separated into five groups. Group 1 considered the control. Groups 2 to 5 were injected 2.5 x 106 EAC intraperitoneally (IP). Injected gp. 2 considered the positive control. Groups 3 and 4 received intraperitoneally injections of arsenic trioxide (ATO) (5 mg/kg) and cisplatin (CIP) (2 mg/kg)) daily for 14 days, while Group 5 received a combination of arsenic trioxide (ATO) (5 mg/kg) and cisplatin (CIP) (0.5 mg/kg)) daily for 14 days. After 14 days of treatment, blood samples were collected. Screening of the medications effects used for EAC treatment are carried out by mice body weights, body weight gain, and tumor growth inhibition by counting total, viable and non-viable tumor cells number for each group. Concurrently, liver functions (transaminases, total protein, and albumin) and kidney functions (urea and creatinine) were evaluated to reflect any clinical changes. The study shown that both ATO and CIP have synergetic properties against EAC. | ||
| Keywords | ||
| Arsenic trioxide; Cisplatin; Ehrlich ascites carcinoma; albino mice | ||
|
Statistics Article View: 264 PDF Download: 803 |
||
